AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16450089
Drug: N-acetylcysteine (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (1,200 mg)
Trial: 8930154
Drug: Naltrexone (3.125,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (3.125, 12.5, 50 and 200 mg)
Trial: 8930154
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cocaine and hydromorphone
Trial: 27311415
Drug: 2000 mg
RxNorm normalized name: bran 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg calcium supplementation
Trial: 27311415
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg calcium supplementation
Trial: 22855866
Drug: Caffeine 100
RxNorm normalized name: caffeine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 100 mg twice daily for 3 weeks, then 200 mg twice daily for 3 weeks
Trial: 20727160
Drug: Wood smoke
RxNorm normalized name: Wood creosote
DrugBank: Wood creosote (DB13271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wood smoke exposure (PM2.5 concentration of 224 ± 22 μg/m3)
Trial: 12818631
Drug: s.c. melagatran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. melagatran (1-3 mg bid) followed by oral ximelagatran (8-24 mg bid)
Trial: 12818631
Drug: s.c. melagatran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. melagatran (3 mg bid) followed by oral ximelagatran (24 mg)
Trial: 12818631
Drug: s.c. enoxaparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. enoxaparin (40 mg od)
Trial: 10353130
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (control group with 9 patients).
Trial: 1773905
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of bacterial extracts over 16 weeks
Trial: 1773905
Drug: Intramuscular benzanthine
RxNorm normalized name: Cephapirin Benzathine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular benzanthine penicillin
Trial: 6258375
Drug: pancuronium 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pancuronium 0.01 mg/kg
Trial: 9424681
Drug: pancuronium 0.015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pancuronium 0.015 mg/kg
Trial: 6258375
Drug: gallamine 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gallamine 0.3 mg/kg
Trial: 6258375
Drug: gallamine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gallamine 0.4 mg/kg
Trial: 24518370
Drug: 1600 μg
RxNorm normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1600 μg of salbutamol
Trial: 21046356
Drug: Rapamycin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapamycin monotherapy (0.1 mg/kg; target trough levels 8-10 ng/ml; 26-314 days)
Trial: 21046356
Drug: Rapamycin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapamycin monotherapy
Trial: 18506181
Drug: Erlotinib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib at 50 mg (cohort 1), 100 mg (cohort 2a), or 75 mg (cohort 2b) day(‐1) for up to six cycles with docetaxel (75 mg m(‐2)) and carboplatin (AUC 5) on day 1 of a 3-week cycle.
Trial: 18506181
Drug: Single-agent maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent maintenance erlotinib at 100-150 mg day(‐1) after initial treatment.
Trial: 10928428
Drug: Crinone 8%
RxNorm normalized name: Crinone 8% Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crinone 8% (90 mg progesterone vaginal gel) twice daily
Trial: 10928428
Drug: Crinone 8%
RxNorm normalized name: Crinone 8% Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crinone 8% (90 mg progesterone vaginal gel) once daily
Trial: 10928428
Drug: i.m. progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.m. progesterone (100 mg)
Trial: 10928428
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (Crinone and i.m. progesterone)
Trial: 1345029
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of ioxaglate
Trial: 1345029
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of iopamidol
Trial: 6205060
Drug: Mezlocillin 2
RxNorm normalized name: mezlocillin 250 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mezlocillin 2 g
Trial: 28258928
Drug: Inhaled mannitol
RxNorm normalized name: mannitol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled mannitol 400mg every 12h for 8 weeks
Trial: 26237001
Drug: Ropivacaine 0.1%
RxNorm normalized name: ROPivacaine 0.1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.1% 10 mL
Trial: 26237001
Drug: Ropivacaine 0.1%
RxNorm normalized name: ROPivacaine 0.1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.1% 30 mL
Trial: 21943294
Drug: Web-based self-help
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based self-help therapy (6-week duration, based on Cognitive Behavioural Therapy, Motivational Interviewing, and self-control practices)
Trial: 21943294
Drug: Web-based self-help
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based self-help therapy
Trial: 21943294
Drug: Weekly psycho-educative
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly psycho-educative information with a quiz (control group)
Trial: 16582527
Drug: Phase I
RxNorm normalized name: Nuvelle TS Phase I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I periodontal treatment including scaling, root planning, and 0.2% chlorhexidine mouth rinse for one week
Trial: 16582527
Drug: Phase I
RxNorm normalized name: Nuvelle TS Phase I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I periodontal treatment
Trial: 8736653
Drug: terbutaline Turbuhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terbutaline Turbuhaler (0.5 mg t.i.d.)
Trial: 8736653
Drug: salbutamol Rotahaler
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: salbutamol Rotahaler (0.4 mg t.i.d.)
Trial: 1434838
Drug: TAD (for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAD (for induction and consolidation) followed by monthly myelosuppressive maintenance for 3 years; second induction course either TAD or HAM for patients less than 60 years.
Trial: 24558403
Drug: recombinant Canarypox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant Canarypox (CP) vaccine vCP205 via inguinal-subcutaneous injection
Trial: 24558403
Drug: recombinant Canarypox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant Canarypox (CP) vaccine vCP205 via deltoid-intramuscular injection
Trial: 24558403
Drug: recombinant Canarypox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant Canarypox (CP) vaccine vCP205
Trial: 22683442
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment (IT) group, n=11
Trial: 10950002
Drug: Topical nitroglycerin
RxNorm normalized name: nitroglycerin Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nitroglycerin 0.25% tid
Trial: 6338064
Drug: Bland oil-in-water
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bland oil-in-water lotion (placebo)
Trial: 27036970
Drug: Online self-help
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Online self-help program for people with HIV and depressive symptoms, duration 6 to 10 weeks, with weekly motivational support from a coach.
Trial: 22314532
Drug: GSK2248761 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2248761 30 mg QD for 7 days
Trial: 22314532
Drug: GSK2248761 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2248761 100 mg QD for 7 days
Trial: 22314532
Drug: GSK2248761 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2248761 200 mg QD for 7 days
Trial: 22314532
Drug: GSK2248761 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2248761 400 mg QD for 7 days
Trial: 22314532
Drug: GSK2248761 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2248761 800 mg QD for 7 days
Trial: 22314532
Drug: GSK2248761 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2248761 (all doses)
Trial: 19596459
Drug: Multifaceted nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifaceted nutritional intervention (chocolate, homemade oral supplements), group exercise (moderate intensity), and oral care
Trial: 10408812
Drug: Bupivacaine 5
RxNorm normalized name: Sure-Amp BUPivacaine 5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 5 mg/ml
Trial: 7769797
Drug: Remikiren 30
RxNorm normalized name: remikiren
DrugBank: Remikiren (DB00212)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remikiren 30 mg
Trial: 7769797
Drug: Remikiren 100
RxNorm normalized name: remikiren
DrugBank: Remikiren (DB00212)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remikiren 100 mg
Trial: 7769797
Drug: Remikiren 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remikiren 1,000 mg
Trial: 2155645
Drug: High intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intensity chemotherapy (cisplatin 120 mg m‐2 i.v. day 1, cyclophosphamide 1,000 mg‐2 i.v. day 1, given at 21‐day intervals for six cycles)
Trial: 2155645
Drug: High intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intensity chemotherapy
Trial: 6107853
Drug: Sulfasalazine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfasalazine (1 g three times a day for six weeks)
Trial: 6107853
Drug: 5-aminosalicylic acid
RxNorm normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminosalicylic acid (0.5 g suppositories three times a day for six weeks)
Trial: 6107853
Drug: Sulfapyridine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfapyridine (0.5 g three times a day for six weeks)
Trial: 27859929
Drug: Diuretic‐induced isosmotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic‐induced isosmotic dehydration to lower SkBF (DEH)
Trial: 27859929
Drug: Continuous saline
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous saline infusion to maintain SkBF (SAL)
Trial: 20648661
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose of vitamin D (880 IU/day)
Trial: 20648661
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of vitamin D (1600 IU/day)
Trial: 11452709
Drug: BAY 12‐9566
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 12‐9566 (50 mg single oral dose)
Trial: 8072252
Drug: Mechanical thrombolysis
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical thrombolysis (M) using heparinized saline as the pulsing agent
Trial: 8072252
Drug: Pharmacomechanical thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacomechanical thrombolysis (PM) using concentrated urokinase as the pulsing agent
Trial: 2522475
Drug: Ipratropium bromide,
RxNorm normalized name: Ipratropium Bromide, compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide, 60 micrograms by metered-dose inhaler
Trial: 21481716
Drug: Maltitol test
RxNorm normalized name: Maltitol
DrugBank: Maltitol (DB16867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltitol test drink (50 g)
Trial: 21481716
Drug: Glucose test
RxNorm normalized name: GLUCOSE TEST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose test drink (50 g)
Trial: 19656102
Drug: Intracoronary administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary administration of stem cells
Trial: 16917170
Drug: Intratympanic gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratympanic gentamicin instillation therapy
Trial: 16917170
Drug: Normal vestibular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal vestibular evoked myogenic potentials before therapy
Trial: 14972474
Drug: Perioperative antibiotics
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative antibiotics (cefazolin and ciprofloxacin)
Trial: 14972474
Drug: No perioperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No perioperative antibiotics (control group)
Trial: 2820298
Drug: Zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc gluconate lozenge (23 mg of elemental zinc), administered 8 times per day for 5 days (trial 1)
Trial: 2820298
Drug: Zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc gluconate lozenge (23 mg of elemental zinc), administered 8 times per day for 7 days (trial 2)
Trial: 2820298
Drug: Zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc gluconate lozenge (23 mg of elemental zinc)
Trial: 22385074
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream for 4 weeks before Mohs micrographic surgery (MMS)
Trial: 22385074
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream for 4 weeks before MMS
Trial: 20399360
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment (medications, physical therapy, lumbar injection)
Trial: 16239154
Drug: Medication for
RxNorm normalized name: SALICYLIC ACID 10 mg in 1 mL TOPICAL LOTION [Serious Skincare Continuously Clear Acne Medication For Problematic skin Dry Lo Pro All- Over Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication for 5 weeks, followed by combined medication plus CBT for 5 weeks
Trial: 16239154
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment for 5 weeks, followed by CBT alone
Trial: 11940259
Drug: Emerging therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emerging therapies in critical care
Trial: 9505999
Drug: Erythromycin 250
RxNorm normalized name: erythromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 250 mg taken orally 4 times daily
Trial: 8180726
Drug: ACE-inhibitors (enalapril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE-inhibitors (enalapril and lisinopril)
Trial: 8180726
Drug: Calcium antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonists (isradipine and felodipine)
Trial: 8180726
Drug: Beta-blockers and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers and/or diuretics
Trial: 24514432
Drug: Unbalanced crystalloid
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unbalanced crystalloid (chloride: 155.5 mmol/l)
Trial: 24514432
Drug: Balanced crystalloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced crystalloid and balanced colloid (6% w/v hydroxyethyl starch 130/0.42; chloride: 98 and 112 mmol/l)
Trial: 22953991
Drug: 30 mCi 131I
RxNorm normalized name: iobenguane (131I)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 30 mCi 131I plus lithium 900 mg/day for 7 days (Group B)
Trial: 21106618
Drug: Integrated motivational
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated motivational interviewing and cognitive behavioural therapy plus standard care
Trial: 18366445
Drug: Nevirapine-containing combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nevirapine-containing combination antiretroviral therapy (NcART)
Trial: 15695788
Drug: Intravenous iodinated
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous iodinated contrast agent (used in part I and part II)
Trial: 15695788
Drug: Limited plain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limited plain CT scan followed by WB intravenous contrast CT scan (used in part II)
Trial: 12642963
Drug: Sugar-coated tablet
RxNorm normalized name: tiopronin
DrugBank: Tiopronin (DB06823)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sugar-coated tablet (50 mg opipramol-2HCl)
Trial: 12642963
Drug: Aqueous solution
RxNorm normalized name: Zephiran Chloride 1:750 Antiseptic Aqueous Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous solution (50 mg opipramol-2HCl)
Trial: 12642963
Drug: Film-coated tablet
RxNorm normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Film-coated tablet (100 mg opipramol-2HCl)
Trial: 12642963
Drug: Sugar-coated tablet
RxNorm normalized name: tiopronin
DrugBank: Tiopronin (DB06823)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sugar-coated tablet (100 mg opipramol-2HCl)
Trial: 11220871
Drug: Grandaxine in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grandaxine in combination with standard therapy
Trial: 8641115
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 mg day‐1
Trial: 24729586
Drug: CYP2A6 -48T→G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2A6 -48T→G polymorphism
Trial: 24729586
Drug: UGT2B7 735
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UGT2B7 735 G/G homozygosity
Trial: 24729586
Drug: CYP2A6 -48T→G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2A6 -48T→G and UGT2B7 735 G/G homozygosity (multivariable model)
Trial: 22335390
Drug: DEX 0.5
RxNorm normalized name: Stri-Dex 0.5 % Medicated Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX 0.5 μg/kg in 10 mL isotonic saline
Trial: 22335390
Drug: DEX 1
RxNorm normalized name: Z-Dex 12 D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX 1 μg/kg in 10 mL isotonic saline
Trial: 22335390
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL isotonic saline (control group)
Trial: 16642609
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment group (acupuncture + Xingnaojing injection)
Trial: 1584592
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine (5 ml of 2% lidocaine)
Trial: 1584592
Drug: Saline (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (5 ml saline)
Trial: 29534465
Drug: Protein supplement
RxNorm normalized name: PROTEIN SUPPLEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein supplement (whey isolate and beef hydrolysate)
Trial: 22235888
Drug: Gel containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel containing niosomes entrapped with rice bran bioactive compounds
Trial: 22235888
Drug: Cream containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream containing niosomes entrapped with rice bran bioactive compounds
Trial: 22235888
Drug: Closed patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed patch test on shaved rabbit skin
Trial: 18520803
Drug: ABT‐751 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT‐751 200 mg daily for 21 consecutive days, followed by 7 days off drug
Trial: 16529564
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (pelvic floor muscle training and duloxetine)
Trial: 1346745
Drug: verapamil 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verapamil 0.05 mg kg‐1
Trial: 1346745
Drug: verapamil 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verapamil 0.1 mg kg‐1
Trial: 1346745
Drug: verapamil (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verapamil (both doses)
Trial: 6513620
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment) in phase 1, then received concurrent reminders in phase 2
Trial: 30373781
Drug: Lactobacillus acidophilus
RxNorm normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus acidophilus tablets combined with quadruple therapy
Trial: 25233647
Drug: Guan's quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guan's quadruple therapy for kidney disease
Trial: 22622628
Drug: Methylphenidate administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate administered for one week
Trial: 18666804
Drug: FDC tablet
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC tablet of repaglinide/metformin 2 mg/500 mg
Trial: 16883914
Drug: Radix Astragali
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radix Astragali Injection